A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
NCT02580058
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Histologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancer.
- Platinum resistant/refractory disease, defined as disease progression within 180 days following the last administered dose of platinum therapy (resistant), or lack of response or disease progression while receiving the most recent platinum based therapy (refractory), respectively.
- Received up to 3 lines of chemotherapy for platinum sensitive disease, most recently platinum containing, and no prior therapy for platinum resistant disease.
- Measurable disease by investigator assessment with at least 1 unidimensional measurable lesion by RECIST v.1.1 that has not previously been irradiated.
- Active autoimmune disease that might deteriorate when receiving an immunostimulatory agents. Patients with diabetes type I, vitiligo, psoriasis, hypo or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
- Non epithelial tumor, including malignant mixed Müllerian tumors without high grade
serous component, or ovarian tumors with low malignant potential (ie, borderline
tumors).
- Prior therapy with an anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti
cytotoxic T lymphocyte associated antigen 4 (CTLA 4) antibody (including ipilimumab,
tremelimumab or any other antibody or drug specifically targeting T cell co
stimulation or immune checkpoint pathways).
- Known symptomatic brain metastases requiring steroids. Patients with previously
diagnosed brain metastases are eligible if they have completed their treatment and
have recovered from the acute effects of radiation therapy or surgery prior to study
entry, have discontinued corticosteroid treatment for these metastases for at least 4
weeks prior to study entry and are neurologically stable.
- Diagnosis of any other malignancy within 5 years prior to registration, except for
adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of
the breast or of the cervix.
- Severe gastrointestinal conditions such as clinical or radiological evidence of bowel
obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4
weeks prior to enrollment, or history of inflammatory bowel disease.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Edmonton, Alberta
- Surrey, British Columbia
- Vancouver, British Columbia
- Halifax, Nova Scotia
- Hamilton, Ontario
- London, Ontario
- Ottawa, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Belo Horizonte, Minas Gerais
- Porto Alegre, Rio Grande Do Sul
- Rio De Janeiro,
- São Paulo,
- São Paulo,
- São Paulo,
- São Paulo,
- The Woodlands, Texas
- Costa Masnaga, Lecco
- Tainan City,
- Roanoke, Virginia
- Copenhagen,
- Kagoshima,
- Cleveland, Ohio
- Seoul,
- Orange, California
- Poznan,
- Bedford, Texas
- Graz,
- Kawasaki, Kanagawa
- Piacenza,
- Shelbyville, Tennessee
- Leuven,
- Taoyuan City,
- Pierre Benite cedex,
- Santa Barbara, California
- Philadelphia, Pennsylvania
- Seoul,
- Caen Cedex 5,
- Dublin,
- Velikiy Novgorod,
- Kernersville, North Carolina
- Cremona,
- Nottingham,
- Calgary, Alberta
- Matsuyama, Ehime
- Louisville, Kentucky
- Praha 2,
- Nice cedex 2,
- Fairway, Kansas
- Asheville, North Carolina
- Krakow,
- London,
- Oslo,
- Boston, Massachusetts
- Prato,
- Singapore,
- Wellington, Florida
- Innsbruck,
- Rogers, Arkansas
- Seoul,
- Nottingham,
- Rybnik,
- Brisbane, Queensland
- Bergen,
- Brussels,
- Tucson, Arizona
- Bergamo,
- Mayfield Heights, Ohio
- Bebington, Wirral, Merseyside
- Dublin 7, Dublin
- Scottsdale, Arizona
- Sutton, Surrey
- Moscow,
- Praha 2,
- Austin, Texas
- Atlanta, Georgia
- Seoul,
- Saint Petersburg,
- Kansas City, Missouri
- Boulder, Colorado
- Cremona,
- Winston-Salem, North Carolina
- Rimini,
- Lugo, Ravenna
- Montreal, Quebec
- Olomouc,
- Phoenix, Arizona
- Milwaukee, Wisconsin
- Chermside, Queensland
- Glasgow,
- Tucson, Arizona
- London,
- Zurich,
- Waterford,
- Fort Worth, Texas
- London,
- Irving, Texas
- Bellinzona, Ticino
- London,
- Chuo-ku, Tokyo
- Goyangsi, Gyeonggi-do
- Cordoba,
- Murfreesboro, Tennessee
- Toon, Ehime
- Madrid,
- Lyon cedex 08,
- Cleveland, Ohio
- Parkville, Victoria
- New Lambton Heights, New South Wales
- Miano, Milano
- Basel, Basel-stadt
- Isehara, Kanagawa
- Winnipeg, Manitoba
- Seoul,
- Auchenflower, Queensland
- Seoul,
- Atlanta, Georgia
- Milwaukee, Wisconsin
- Gallatin, Tennessee
- Mayfield Heights, Ohio
- Candiolo, Torino
- Philadelphia, Pennsylvania
- Daytona Beach, Florida
- Cleveland, Ohio
- Praha 2, Czech Republic
- Dublin,
- Parkville, Victoria
- Taipei City,
- Bethesda, Maryland
- Northwood, Middlesex
- Herston, Queensland
- Bunkyo-ku, Tokyo
- Taipei,
- Manerbio, Brescia
- Zurich,
- Yokohama, Kanagawa
- Boston, Massachusetts
- Girona,
- Vandoeuvre-lès-Nancy,
- London,
- Dublin 4,
- Taoyuan City,
- L'Hospitalet de Llobregat, Barcelona
- Seoul,
- Aurora, Colorado
- Asheville, North Carolina
- Prato,
- Boston, Massachusetts
- Kelowna, British Columbia
- Parkville, Victoria
- Louisville, Kentucky
- Madrid,
- Douglasville, Georgia
- Glasgow, CITY OF Glasgow
- Cartersville, Georgia
- Krakow,
- Singapore,
- Daegu,
- Taipei City,
- Westwood, Kansas
- Toronto, Ontario
- Chelyabinsk,
- Austell, Georgia
- Stockport,
- Edmonton, Alberta
- Halifax, Nova Scotia
- Headington, Oxford
- West Palm Beach, Florida
- Winnipeg, Manitoba
- South Brisbane, Queensland
- Halifax, Nova Scotia
- Silver Spring, Maryland
- Hermitage, Tennessee
- Toronto, Ontario
- Tsukuba, Ibaraki
- Hamamatsu, Shizuoka
- Taipei,
- Oslo,
- Luzern 16, Luzern
- Newcastle, New South Wales
- Dickson, Tennessee
- Gent, EAST Flanders
- Herston, Queensland
- Melbourne, Victoria
- Albuquerque, New Mexico
- Namur,
- Nashville, Tennessee
- Taipei city,
- London,
- Dublin 4,
- Piacenza,
- Praha 5,
- Zurich,
- Fayetteville, Arkansas
- Bebington, Wirral, Merseyside
- Silver Spring, Maryland
- Winnipeg, Manitoba
- Pyatigorsk, Stavropol Region
- Taipei City,
- Taipei,
- Hidaka, Saitama
- Brescia,
- Debrecen,
- Paris cedex 15,
- Nashville, Tennessee
- Nizhniy Novgorod,
- Nashville, Tennessee
- Niigata,
- Louisville, Kentucky
- Louisville, Kentucky
- Nashville, Tennessee
- Kortrijk,
- Phoenix, Arizona
- Kita-adachi-gun, Saitama
- Philadelphia, Pennsylvania
- Ottawa, Ontario
- Singapore,
- Maastricht,
- Chelyabinsk,
- Praha 2,
- Aalborg,
- Roanoke, Virginia
- Austin, Texas
- Montreal, Quebec
- Marietta, Georgia
- Torino,
- Milano,
- Dublin,
- Franklin, Tennessee
- Sutton, Surrey
- Poznan,
- Dublin 7, Dublin
- Sapporo, Hokkaido
- Irving, Texas
- Southport, Queensland
- Hong Kong,
- Ostrava-Poruba,
- Malvern, Victoria
- Cleveland, Ohio
- Budapest,
- Manchester,
- Lakewood, Colorado
- Singapore,
- Groningen,
- Lebanon, Tennessee
- Smyrna, Tennessee
- Paris,
- Rybnik,
- Seoul,
- Reno, Nevada
- Nashville, Tennessee
- Zurich,
- South Brisbane, Queensland
- Athens/New Kifissia,
- Debrecen,
- Chandler, Arizona
- Krasnodar,
- Tainan city,
- Atlanta, Georgia
- Auchenflower, Queensland
- Kagoshima,
- Liege,
- Cleveland, Ohio
- Groningen,
- Herston, Queensland
- Jerusalem,
- Tempe, Arizona
- Sochi, Krasnodar Region
- Seoul,
- San Antonio, Texas
- Usti nad Labem,
- Olsztyn,
- Louisville, Kentucky
- Brighton, Victoria
- Orenburg,
- Seoul,
- Sendai, Miyagi
- Salt Lake City, Utah
- Cambridge, Cambridgeshire
- Tokorozawa, Saitama
- Cremona,
- Seoul,
- Bergen,
- Solvang, California
- Montreal, Quebec
- Szolnok,
- Bergamo,
- Albuquerque, New Mexico
- Northampton, Northamptonshire
- Bergamo,
- South Brisbane, Queensland
- Boston, Massachusetts
- Taipei City,
- Olsztyn,
- Madrid,
- Zurich,
- Columbia, Maryland
- Vancouver, British Columbia
- Daegu,
- Shimotsuke, Tochigi
- Basel, Basel-stadt
- Athens,
- Eugene, Oregon
- Hong Kong,
- Villejuif cedex,
- Akashi, Hyogo
- Carrollton, Georgia
- Louisville, Kentucky
- Budapest,
- Leiden,
- Singapore,
- Louisville, Kentucky
- Sevilla,
- Como,
- Chandler, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Scottsdale, Arizona
- Tempe, Arizona
- Tucson, Arizona
- Tucson, Arizona
- Fayetteville, Arkansas
- Rogers, Arkansas
- Orange, California
- Santa Barbara, California
- Solvang, California
- Aurora, Colorado
- Boulder, Colorado
- Lakewood, Colorado
- Daytona Beach, Florida
- Wellington, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Austell, Georgia
- Carrollton, Georgia
- Cartersville, Georgia
- Douglasville, Georgia
- Marietta, Georgia
- Fairway, Kansas
- Westwood, Kansas
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Bethesda, Maryland
- Columbia, Maryland
- Silver Spring, Maryland
- Silver Spring, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Kansas City, Missouri
- Reno, Nevada
- Albuquerque, New Mexico
- Albuquerque, New Mexico
- Asheville, North Carolina
- Asheville, North Carolina
- Kernersville, North Carolina
- Winston-Salem, North Carolina
- Cleveland, Ohio
- Cleveland, Ohio
- Cleveland, Ohio
- Cleveland, Ohio
- Cleveland, Ohio
- Mayfield Heights, Ohio
- Mayfield Heights, Ohio
- Eugene, Oregon
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Dickson, Tennessee
- Franklin, Tennessee
- Gallatin, Tennessee
- Hermitage, Tennessee
- Lebanon, Tennessee
- Murfreesboro, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Shelbyville, Tennessee
- Smyrna, Tennessee
- Austin, Texas
- Austin, Texas
- Bedford, Texas
- Fort Worth, Texas
- Irving, Texas
- Irving, Texas
- San Antonio, Texas
- The Woodlands, Texas
- Salt Lake City, Utah
- Roanoke, Virginia
- Roanoke, Virginia
- Milwaukee, Wisconsin
- Milwaukee, Wisconsin
- New Lambton Heights, New South Wales
- Newcastle, New South Wales
- Auchenflower, Queensland
- Auchenflower, Queensland
- Brisbane, Queensland
- Chermside, Queensland
- Herston, Queensland
- Herston, Queensland
- Herston, Queensland
- South Brisbane, Queensland
- South Brisbane, Queensland
- South Brisbane, Queensland
- Southport, Queensland
- Brighton, Victoria
- Malvern, Victoria
- Melbourne, Victoria
- Parkville, Victoria
- Parkville, Victoria
- Parkville, Victoria
- Graz,
- Innsbruck,
- Gent, EAST Flanders
- Brussels,
- Kortrijk,
- Leuven,
- Liege,
- Namur,
- Calgary, Alberta
- Edmonton, Alberta
- Kelowna, British Columbia
- Vancouver, British Columbia
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- Halifax, Nova Scotia
- Halifax, Nova Scotia
- Ottawa, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Praha 2, Czech Republic
- Olomouc,
- Ostrava-Poruba,
- Praha 2,
- Praha 2,
- Praha 2,
- Praha 5,
- Usti nad Labem,
- Aalborg,
- Copenhagen,
- Caen Cedex 5,
- Lyon cedex 08,
- LYON cedex 8,
- Nice cedex 2,
- Paris cedex 15,
- Paris,
- Pierre Benite cedex,
- Vandoeuvre-lès-Nancy,
- Villejuif cedex,
- Athens/New Kifissia,
- Athens,
- Hong Kong,
- Hong Kong,
- Budapest,
- Budapest,
- Debrecen,
- Debrecen,
- Szolnok,
- Dublin 7, Dublin
- Dublin 7, Dublin
- Dublin 4,
- Dublin 4,
- Dublin,
- Dublin,
- Dublin,
- Waterford,
- Jerusalem,
- Manerbio, Brescia
- Costa Masnaga, Lecco
- Miano, Milano
- Lugo, Ravenna
- Candiolo, Torino
- Bergamo,
- Bergamo,
- Bergamo,
- Brescia,
- Como,
- Cremona,
- Cremona,
- Cremona,
- Milano,
- Piacenza,
- Piacenza,
- Prato,
- Prato,
- Rimini,
- Torino,
- Matsuyama, Ehime
- Toon, Ehime
- Sapporo, Hokkaido
- Akashi, Hyogo
- Tsukuba, Ibaraki
- Isehara, Kanagawa
- Kawasaki, Kanagawa
- Yokohama, Kanagawa
- Sendai, Miyagi
- Hidaka, Saitama
- Kita-adachi-gun, Saitama
- Tokorozawa, Saitama
- Hamamatsu, Shizuoka
- Shimotsuke, Tochigi
- Bunkyo-ku, Tokyo
- Chuo-ku, Tokyo
- Kagoshima,
- Kagoshima,
- Niigata,
- Goyangsi, Gyeonggi-do
- Daegu,
- Daegu,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Groningen,
- Groningen,
- Leiden,
- Maastricht,
- Bergen,
- Bergen,
- Oslo,
- Oslo,
- Krakow,
- Krakow,
- Olsztyn,
- Olsztyn,
- Poznan,
- Poznan,
- Rybnik,
- Rybnik,
- Sochi, Krasnodar Region
- Pyatigorsk, Stavropol Region
- Chelyabinsk,
- Chelyabinsk,
- Krasnodar,
- Moscow,
- Nizhniy Novgorod,
- Orenburg,
- Saint Petersburg,
- Velikiy Novgorod,
- Singapore,
- Singapore,
- Singapore,
- Singapore,
- Singapore,
- L'Hospitalet de Llobregat, Barcelona
- Cordoba,
- Girona,
- Madrid,
- Madrid,
- Madrid,
- Sevilla,
- Basel, Basel-stadt
- Basel, Basel-stadt
- Luzern 16, Luzern
- Bellinzona, Ticino
- Zurich,
- Zurich,
- Zurich,
- Zurich,
- Zurich,
- Tainan city,
- Tainan City,
- Taipei city,
- Taipei City,
- Taipei City,
- Taipei City,
- Taipei City,
- Taipei,
- Taipei,
- Taipei,
- Taoyuan City,
- Taoyuan City,
- Cambridge, Cambridgeshire
- Glasgow, CITY OF Glasgow
- Bebington, Wirral, Merseyside
- Bebington, Wirral, Merseyside
- Northwood, Middlesex
- Northampton, Northamptonshire
- Headington, Oxford
- Sutton, Surrey
- Sutton, Surrey
- Glasgow,
- London,
- London,
- London,
- London,
- London,
- London,
- Manchester,
- Nottingham,
- Nottingham,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | ||||||
Official Title ICMJE | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER | ||||||
Brief Summary | A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with platinum resistant/platinum refractory ovarian cancer. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 3 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||||
Condition ICMJE | Ovarian Cancer | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Active, not recruiting | ||||||
Actual Enrollment ICMJE | 566 | ||||||
Original Estimated Enrollment ICMJE | 550 | ||||||
Estimated Study Completion Date ICMJE | December 31, 2021 | ||||||
Actual Primary Completion Date | September 19, 2018 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Mandatory tumor biopsy must be performed prior to enrollment for all patients (unless there is a documented clinical contraindication). In addition, availability of archived FFPE tumor tissue should be confirmed. If a patient underwent tumor tissue collection within 3 months prior to enrollment with no intervening treatment, and the sample is provided, then a new de novo tumor biopsy is not required. Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Norway, Poland, Russian Federation, Singapore, Spain, Switzerland, Taiwan, United Kingdom, United States | ||||||
Removed Location Countries | Czech Republic | ||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT02580058 | ||||||
Other Study ID Numbers ICMJE | B9991009 2015-003091-77 ( EudraCT Number ) JAVELIN OVARIAN 200 ( Other Identifier: Alias Study Number ) | ||||||
Has Data Monitoring Committee | Not Provided | ||||||
U.S. FDA-regulated Product | Not Provided | ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | January 2021 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |